Monoclonal Antibody to Macrophage Inflammatory Protein 5 (MIP5)
Code | Size | Price |
---|
MAA550Hu21-20ul | 20ul | £85.00 |
Quantity:
MAA550Hu21-100ul | 100ul | £156.00 |
Quantity:
MAA550Hu21-200ul | 200ul | £210.00 |
Quantity:
MAA550Hu21-1ml | 1ml | £480.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
CCL15; SCYA15; HCC-2; NCC-3; SCYL3; Lkn-1; MIP1-D; MIP1d; MIP-1d; HMRP-2B; Leukotactin-1; Chemokine C-C-Motif Ligand 15; MIP-1 Delta; Small-inducible cytokine A15
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Macrophage Inflammatory Protein 5
Potency (Clone Number):
C1
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:500-5000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Macrophage Inflammatory Protein 5 (MIP5) | RPA550Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||